Drug Interaction Between Erlotinib and Itraconazole in a Patient With Non–Small Cell Lung Cancer
Open Access
- 1 January 2026
- journal article
- case report
- Published by Wiley in Case Reports in Oncological Medicine
- Vol. 2026 (1)
Abstract
Introduction: Erlotinib (ERL) is metabolized primarily by cytochrome P450 (CYP) 3A4. We report a case of non–small cell lung cancer in which plasma ERL concentrations increased following coadministration of itraconazole (ITCZ). Case Presentation: In this patient, a 67‐year‐old man receiving ERL 150 mg/day, the trough plasma concentration ( C 0 ) of ERL and its major metabolite, O‐desmethyl ERL (OSI‐420), increased following coadministration of ITCZ. The total clearance of ERL at steady state was 6.1 L/h. The mean C 0 of ERL and OSI‐420 were 437 and 47.1 ng/mL, respectively, and the C 0 ratio of OSI‐420/ERL was 0.108. With coadministration of oral ITCZ (200 mg/day capsule), the mean C 0 of ERL and OSI‐420 increased to 1124 and 166 ng/mL, respectively, and the mean C 0 ratio of OSI‐420/ERL increased to 0.147. The mean C 0 of ITCZ and the sum of ITCZ and the active metabolite hydroxyitraconazole (OH‐ITCZ) were 109 and 271 ng/mL, respectively. The mean C 0 of ERL increased approximately 2.5‐fold. Conclusion: Even at the relatively lower C 0 of ITCZ (compared with the recommended target value), ITCZ coadministration increased the C 0 of ERL. In patients with a sufficient ERL C 0 of more than 500 ng/mL prior to ITCZ coadministration or patients exhibiting adequate absorption of oral ITCZ, the risk of ERL‐related adverse events with ITCZ coadministration may increase due to further elevation of the ERL C 0 . Therefore, when ERL is coadministered with ITCZ, careful monitoring for adverse effects and appropriate dose adjustments are required, considering potential changes in ERL concentrations. Management using the C 0 of ERL and ITCZ may be necessary.Keywords
Funding Information
- Japan Society for the Promotion of Science (25H00265)
This publication has 18 references indexed in Scilit:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Accurate Prediction of Dose-Dependent CYP3A4 Inhibition by Itraconazole and Its Metabolites From In Vitro Inhibition DataClinical Pharmacology & Therapeutics, 2010
- Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100British Journal of Cancer, 2008
- Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2008
- The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibitionEuropean Journal of Clinical Pharmacology, 2007
- Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 EnzymesClinical Cancer Research, 2007
- Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumorsCancer Chemotherapy and Pharmacology, 2007
- METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERSDrug Metabolism and Disposition, 2006
- Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid MalignanciesJournal of Clinical Oncology, 2001